Inactive Instrument

Highlights Aimmune Therapeutics, Inc.

Equities

AIMT

US00900T1079

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Aimmune Therapeutics, Inc. to Present Positive Results from Phase 3 POSEIDON Study of PALFORZIAÂ« [Peanut (Arachis Hypogaea) Allergen Powder-dnfp] in Peanut-Allergic Children Aged 1 to 3 Years	22-11-10	CI
Allergy Partners Announces Strategic Collaboration with Aimmune Therapeutics, Inc. to Provide PALFORZIA® Directly to Patients	22-10-13	CI
Aimmune Therapeutics, Inc. Announces Publication of Pooled Safety Analysis of PALFORZIA® Treatment for Up to 2 Years in the Journal of Allergy and Clinical Immunology	22-02-16	CI
Aimmune Therapeutics, Inc. Presents New PALFORZIA?	21-11-12	CI
Aimmune Therapeutics Launches the First Real-World Registry Study for Patients with Chronic Pancreatitis	21-06-08	CI
Aimmune Therapeutics Announces New Clinical Data from A Pooled Analysis of Three Controlled Phase 3	21-02-25	CI
Aimmune Therapeutics, Inc. Receives Positive CHMP Opinion on PALFORZIA® for the Treatment of Patients with Peanut Allergy in Europe	20-10-16	CI
Aimmune Therapeutics : Nestle Completes Purchase of Aimmune Therapeutics Shares; Plans Merger With Subsidiary	20-10-13	DJ
Société des Produits Nestlé S.A. completed the acquisition of additional 80.6% stake in Aimmune Therapeutics, Inc. from a group of shareholders.	20-10-08	CI
Nestle S A : Nestlé Buys Biopharma Maker Of Peanut-Allergy Treatment	20-09-01	DJ
Aimmune Therapeutics : Nestle gets peanut allergy treatment with $2 billion Aimmune buyout	20-08-31	RE
Aimmune Therapeutics : Nestle gets peanut allergy treatment with $2 billion Aimmune buyout	20-08-31	RE
Nestle S A : Nestlé Moves Further Into Health, Buying Peanut-Allergy Treatment Maker -- Update	20-08-31	DJ
Aimmune Therapeutics : Nestle Health Science to Acquire Aimmune Therapeutics at $2.6 Billion Valuation	20-08-31	DJ
Société des Produits Nestlé S.A. signed a definitive agreement to acquire an additional 80.6% stake in Aimmune Therapeutics, Inc. from a group of shareholders for $1.8 billion.	20-08-30	CI
Aimmune Therapeutics, Inc. Provides Full Results of Aimmune’s Pivotal Phase 3 European Artemis Trial of Palforzia Published in the Lancet Child & Adolescent Health	20-07-21	CI
Aimmune Therapeutics, Inc. Announces New Two-Year Data That Suggest Long-Term Efficacy of Daily Treatment with PALFORZIA	20-06-08	CI
Aimmune Therapeutics, Inc. Announces New Palforzia™ Data on Long-Term Safety, Efficacy and Immunomodulation and New Data on Patient Satisfaction with Palforzia Treatment to Be Presented At Eaaci 2020 Congress	20-06-01	CI
Aimmune Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-11	CI
Aimmune Therapeutics, Inc. Announces First U.S. Patients Are Being Treated with Newly-Approved PALFORZIA, the First Treatment for Peanut Allergy	20-03-16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Aimmune Therapeutics, Inc.

Equities

AIMT

US00900T1079

Highlights

Filters